Navigation Links
SGX Pharmaceuticals BCR-ABL Program to be Presented at the American Society of Hematology 49th Annual Meeting and Exposition

SAN DIEGO, Dec. 6 /PRNewswire-FirstCall/ -- SGX Pharmaceuticals, Inc. (Nasdaq: SGXP) announced today details of two presentations from the Company's BCR-ABL program for the treatment of chronic myelogenous leukemia (CML) at the upcoming American Society of Hematology's 49th Annual Meeting and Exposition. The conference is being held December 8th - 11th, 2007 in Atlanta, Georgia.

The schedule for these sessions, together with the abstract information, is listed below:

Date: Saturday, December 8, 2007 from 5:30pm - 7:30pm EST

Session Type: Poster Session, Board #172-I

Abstract: #1018

Title: "Co-Crystal Structures of 7-Azaindole Inhibitors of

Wild-Type and T315I Imatinib-Resistant Mutant Forms of the

BCR-ABL Tyrosine Kinase."

Description: This poster presentation describes how the SGX393 chemical

family of BCR-ABL inhibitors discovered by SGX can provide

potent, selective inhibition of both wild type and major

drug resistant mutant forms of BCR-ABL including T315I.

The poster discusses the impact of seven BCR-ABL mutations

on the co-crystal structures of the SGX393 family of

inhibitors, including the challenging T315I, G250E and

F317L mutations. SGX393 represents an illustrative example

of how the integrated SGX FAST fragment-based,

structure-guided drug discovery platform can be used to

generate high-quality, low molecular weight inhibitors of

oncology targets.

Date: Monday, December 10, 2007 from 1:30pm - 3:00pm EST

Session Type: Oral Session

Abstract: #535

Title: "SGX70393 Inhibits BCR-ABL & T315I In Vitro and In Vivo

and Completely Suppresses Resistance When Combined with

Nilotinib or Dasatinib."

Description: An oral presentation, coauthored with collaborators at the

Oregon Health & Science University Cancer Institute,

describes a proof of principle study demonstrating the

potential of combination targeted therapy for CML. SGX393

(also known as SGX70393) is a potent, selective

orally-bioavailable inhibitor of both wild type and major

drug resistant mutant forms of BCR-ABL, including the most

challenging T315I mutation.

"These two ASH presentations explain how SGX is using its

drug discovery platform to discover and optimize potent,

selective and orally-bioavailable inhibitors of important

oncology drug discovery targets," said Stephen Burley,

Chief Scientific Officer of SGX Pharmaceuticals.

"Moreover, the results obtained with our collaborators at

the Oregon Health & Science University Cancer Institute

demonstrate the potential of targeted combination therapy

for CML. A number of influential thought leaders believe

that effective management of newly-diagnosed CML will

depend on long-term treatment with multiple agents

possessing non-overlapping resistance profiles."

About the SGX BCR-ABL Program

SGX393 is an internally developed, orally-bioavailable, small molecule inhibitor of the abnormal BCR-ABL tyrosine kinase, which results from a characteristic chromosome abnormality (also known as the Philadelphia chromosome) that causes chronic myelogenous leukemia or CML, a cancer of the bone marrow. SGX393 has shown both potent in vitro blockade of the activity of BCR-ABL and in vivo activity against human leukemic cells that depend on BCR-ABL for their uncontrolled growth and proliferation. In addition, SGX393 has shown potent activity against a broad spectrum of mutant forms of BCR-ABL that render this cancer target resistant to imatinib (Gleevec (R)), the current standard of care for CML. One of the key drug resistant forms of BCR-ABL inhibited by SGX393 is the T315I mutation, which is also resistant to the two second-generation BCR-ABL inhibitors, nilotinib (Tasigna (R)) and dasatinib (Sprycel (R)). In addition, SGX is engaged in a strategic collaboration with Novartis that aims to discover and develop next generation BCR-ABL inhibitors for treatment of newly-diagnosed CML patients.

About SGX Pharmaceuticals

SGX Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of innovative cancer therapeutics. The SGX oncology pipeline includes drug candidates from its FAST(TM) drug discovery platform, such as next generation BCR-ABL inhibitors being developed by SGX and in partnership with Novartis and cMET tyrosine kinase inhibitors, including SGX523, and JAK2 inhibitors. More information on the pipeline and drug discovery platform can be found at and in the Company's various filings with the Securities and Exchange Commission.

Forward-looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements include, but are not limited to, research and development programs, the potential of SGX's BCR-ABL inhibitors as treatments for chronic myelogenous leukemia and the ability to discover, develop and commercialize cancer therapeutics. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug discovery, development and commercialization. The results of early preclinical studies or clinical trials may not be predictive of future results, and the Company cannot provide any assurances that any of its compounds or development candidates will have favorable results in preclinical studies or future clinical trials. For a discussion of these and other factors, please refer to the risk factors described in the Company's annual report on Form 10-K for the year ended December 31, 2006, the Company's quarterly report on Form 10-Q for the three and nine months ended September 30, 2007, as well as other filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and SGX undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

SOURCE SGX Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
7. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
9. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
10. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
11. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
Post Your Comments:
(Date:11/24/2015)... ... November 24, 2015 , ... In an article ... variables that determine which patients are or are not eligible for bariatric surgery. The ... BMI over 40, are more than 100 pounds overweight, or have a BMI of ...
(Date:11/24/2015)... ... 24, 2015 , ... It takes only three to five seconds to make ... the first impression be positive and reflects business values. If a client starts with ... want to return. They will also share their thoughts about a business with others, ...
(Date:11/24/2015)... ... 24, 2015 , ... Cancer patients, survivors, caregivers, family members ... live taping of the next CURE Connections® video series on Saturday, ... Symposium at Georgetown University Hotel & Conference Center in Washington, D.C. , CURE ...
(Date:11/24/2015)... ... November 24, 2015 , ... Aided by seed funding from the ... study designed to yield insights into how to detect and treat pancreatic cancer (PC). ... cancer from small, non-coding RNA molecules (ncRNA), genetic material that is present in the ...
(Date:11/24/2015)... ... 2015 , ... Sir Grout of Baltimore is proud to ... award recognizes good companies for excellence in service and a commitment to the ... surface restoration company earned this recognition after a thorough review by the acclaimed ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... Connecticut , November 24, 2015 ... of Acadiana has entered into a multi-year agreement ... imaging centers. This investment will provide the Breast Center ... --> Sectra (STO: SECT B) announces that ... agreement to deploy Breast Imaging PACS in its ...
(Date:11/24/2015)... , Nov. 24, 2015  Ascendant Solutions, Inc. (Pink Sheets: ... its Board of Directors has declared a special 1 percent ... dividend is payable December 14, 2015, to shareholders of record ... form of additional shares of common stock. ... Board is a strong endorsement of our confidence in Ascendant,s ...
(Date:11/24/2015)... -- iRhythm Technologies, Inc. , a leading digital health care ... will participate in the 27th Annual Piper Jaffray Healthcare Conference at ... . Kevin King , Chief Executive Officer of ... 8:50am ET. --> --> ... . --> iRhythm is a privately held ...
Breaking Medicine Technology: